Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, May 16, 2022
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
[ Mon, May 16th 2022
] - WOPRAI
Ed Arce Maintained (AKBA) at Hold with Decreased Target to $1.25 on, May 16th, 2022
Ed Arce of HC Wainwright & Co., Maintained "Akebia Therapeutics, Inc." (AKBA) at Hold with Decreased Target from $2 to $1.25 on, May 16th, 2022.
Ed has made no other calls on AKBA in the last 4 months.
There are 3 other peers that have a rating on AKBA. Out of the 3 peers that are also analyzing AKBA, all agree with Ed's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $2 on, Thursday, March 31st, 2022
- Difei Yang of "Mizuho" Downgraded from Strong Buy to Hold and Decreased Target to $2 on, Thursday, March 31st, 2022
- Serge Belanger of "Needham" Downgraded from Strong Buy to Hold on, Thursday, March 31st, 2022
